Chronic Obstructive Pulmonary Disease Treatment Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

Feb 2019| TMR1347A| Transparency

Report Highlights

Global Chronic Obstructive Pulmonary Disease Treatment Market: Overview

This report analyzes the current and future scenario of the global chronic obstructive pulmonary disease (COPD) treatment market. Rise in prevalence of COPD, increase in the adoption of combination therapy, and surge in awareness about COPD treatment are the key factors anticipated to drive the global market. Additionally, increase in the geriatric population, rise in importance of COPD management, and surge in the number of respiratory care centers contribute to the growth of the global market. According to the Global Initiative for Asthma (GINA) 2018, COPD is the third leading cause of death in the U.S., with large portion of population being undiagnosed.

The global chronic obstructive pulmonary disease treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global chronic obstructive pulmonary disease treatment market.

New drug development by market players through collaborations and increase in research and development expenditure are anticipated to drive the global market. In February 2016, Propeller Health and Novartis Pharma AG entered into collaboration to develop a custom add-on sensor for the Breezhaler inhaler, a device indicated for COPD treatments. This collaboration aims to connect these medications to Propeller’s digital health platform..

Global Chronic Obstructive Pulmonary Disease Treatment Market: Key Segments

In terms of drug class, the global chronic obstructive pulmonary disease treatment market has been segmented into combination, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokineticsm and others. The combination segment has been divided into long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, and others. The bronchodilators segment has been classified into long acting beta agonist (LABA), short acting beta agonist (SABA), and long acting muscarinic antagonist (LAMA). Based on distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is projected to expand at the fastest CAGR due to increase in the number of patients preferring retail pharmacies. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Chronic Obstructive Pulmonary Disease Treatment Market: Regional Outlook

In terms of region, the global chronic obstructive pulmonary disease treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global chronic obstructive pulmonary disease treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players profiled in the market report include AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline plc, Novartis AG, CHIESI Farmaceutici S.p.A., Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd), Teva Pharmaceutical Industries Ltd, Mylan N.V., and Orion Corporation.
The global chronic obstructive pulmonary disease treatment market has been segmented as below:

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class
Combination
Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
Triple Therapy
Others
Bronchodilators
Long Acting Beta Agonist (LABA)
Short Acting Beta Agonist (SABA)
Long Acting Muscarinic Antagonist (LAMA)
Corticosteroids
Phosphodiesterase Type 4 Inhibitors
Mucokinetics
Others
 
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
 
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa

  • Table 1 : Pipeline Analysis
  • Table 2 : Pipeline Analysis
  • Table 3 : Pipeline Analysis
  • Table 4 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 5 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
  • Table 6 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
  • Table 7 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 8 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Region, 2016–2026
  • Table 9 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 10 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
  • Table 11 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
  • Table 12 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 13 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country, 2016–2026
  • Table 14 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 15 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
  • Table 16 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
  • Table 17 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 18 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 19 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 20 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
  • Table 21 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
  • Table 22 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 23 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 24 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 25 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
  • Table 26 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
  • Table 27 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 28 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 29 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 30 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
  • Table 31 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
  • Table 32 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 33 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Figure 1 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
  • Figure 2 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Drug Class, 2017
  • Figure 3 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 4 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 5 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Combination, 2016–2026
  • Figure 6 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Bronchodilators, 2016–2026
  • Figure 7 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Corticosteroids, 2016–2026
  • Figure 8 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Phosphodiesterase Type 4 Inhibitors, 2016–2026
  • Figure 9 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Mucokinetics, 2016–2026
  • Figure 10 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
  • Figure 11 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 12 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 13 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2016–2026
  • Figure 14 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Independent Pharmacies, 2016–2026
  • Figure 15 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016–2026
  • Figure 16 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
  • Figure 17 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region, 2017 and 2026
  • Figure 18 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region, 2018–2026
  • Figure 19 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 20 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 21 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 22 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 23 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018 - 2026
  • Figure 24 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 25 : North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country, 2018–2026
  • Figure 26 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 27 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 28 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 29 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 30 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018 - 2026
  • Figure 31 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 32 : Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 33 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 34 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 35 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 36 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 37 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
  • Figure 38 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 39 : Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 40 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 41 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 42 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 43 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 44 : Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 45 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
  • Figure 46 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 47 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
  • Figure 48 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 49 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
  • Figure 50 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 51 : Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
  • Figure 52 : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share, by Company, 2017
  • Figure 53 : AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 54 : AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 55 : AstraZeneca Breakdown of Net Sales (%), by Region, 2017
  • Figure 56 : AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2017
  • Figure 57 : Boehringer Ingelheim International GmbH , Human Pharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 58 : Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 59 : Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2017
  • Figure 60 : Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 61 : GlaxoSmithKline plc Respiratory Business Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 62 : GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 63 : GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2017
  • Figure 64 : GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 65 : Novartis AG COPD Portfolio Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 66 : Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 67 : Novartis AG Breakdown of Net Sales (%), by Country, 2017
  • Figure 68 : Novartis AG Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 69 : Teva Pharmaceutical Industries Ltd Respiratory Medicine Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 70 : Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 71 : Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Region, 2017
  • Figure 72 : Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 73 : Sumitomo Dainippon Pharma Co., Ltd Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 74 : Sumitomo Dainippon Pharma Co., Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 75 : Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Region, 2017
  • Figure 76 : Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Product Segment, 2017
  • Figure 77 : CHIESI Farmaceutici S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 78 : CHIESI Farmaceutici S.p.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 79 : CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Region, 2017
  • Figure 80 : CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Therapeutics Area, 2017
  • Figure 81 : Orion Corporation Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 82 : Orion Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 83 : Orion Corporation Breakdown of Net Sales (%), by Country, 2017
  • Figure 84 : Orion Corporation Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 85 : Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 86 : Mylan N.V. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
  • Figure 87 : Mylan N.V. Breakdown of Net Sales (%), by Region, 2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report